Anxiety
Conditions
Brief summary
To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
Detailed description
duloxetine 60 to 120 mg once daily (QD) and placebo 11 weeks
Interventions
DRUGduloxetine
DRUGplacebo
Sponsors
Boehringer Ingelheim
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female outpatients at least 18 years of age presenting with generalized anxiety disorder (GAD) based on the disease diagnostic criteria The patient must suffer from GAD and not from an adjustment disorder or anxiety disorder not otherwise specified (NOS). Symptoms of GAD should not be situational in nature. * Females of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who are not breastfeeding; test negative for pregnancy at the time of enrollment based on a urine pregnancy test; and agree to use a reliable method of birth control during the study and for 1 week following the last dose of study drug. * Must have a Clinical Global Impressions of Severity (CGI-Severity) score of greater than or equal to 4 at Visit 1 and Visit 2. * At Visit 1, patient must have a Covi Anxiety Scale (CAS) score of greater than or equal to 9, no item in the Raskin Depression Scale (RDS) may be greater than 3, and the CAS must be greater than the RDS. * Must have a Hospital Anxiety and Depression Scale (HADS) anxiety subscale score of greater than or equal to 10 at Visit 1.
Exclusion criteria
* Any current and primary DSM-IV Axis I diagnosis other than GAD. * Patients diagnosed with or who have a history of major depressive disorder (MDD) within the past 6 months or * Patients diagnosed with or who have a history of Panic Disorder, Post-Traumatic Stress Disorder (PTSD), or an eating disorder within the past year or * Patients who have been diagnosed with Obsessive Compulsive Disorder (OCD), Bipolar Affective Disorder, psychosis, factitious disorder, or somatoform disorders during their lifetime. * The presence of an Axis II disorder or history of antisocial behavior, which, in the judgment of the investigator, would interfere with compliance with the study protocol. * Benzodiazepine use 14 days prior to Visit 2. * Patients judged clinically to be at serious suicidal risk, or patients who, in the opinion of the investigator, are poor medical or psychiatric risks for study completion. * Have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Rating Scale (HAMA) total score (Hamilton 1959) | — |
Secondary
| Measure | Time frame |
|---|---|
| Sheehan Disability Scale (SDS) Global Functional Impairment score (Sheehan 1983) | — |
| Hospital Anxiety Depression Scale (HADS; Zigmond and Snaith 1983) | — |
| Clinical Global Impressions of Improvement scale (CGI-Improvement; Guy 1976) | — |
| Patient's Global Impressions of Improvement scale (PGI-Improvement; Guy 1976) | — |
| Symptom Questionnaire-Somatic Subscale (SQ-SS) | — |
Countries
United States
Outcome results
None listed